Drugs / AZP2006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04008355 | Jun 2020 → Jul 2022 | progressive supranuclear palsy | AlzProtect SAS | Completed | Met primary |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-08-24 | AlzProtect SAS | Regulatory ALZPROTECT Receives U.S. FDA Fast Track Designation for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP) alzprotect.com ↗
Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). |
| 2026-05-19 | AlzProtect SAS | Regulatory ALZPROTECT Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP) alzprotect.com ↗ |
| 2023-09-21 | AlzProtect SAS | Results ALZPROTECT DEVELOPS AN INNOVATIVE TREATMENT AND EXPANDS ITS CLINICAL TRIALS, FOLLOWING VERY POSITIVE RESULT alzprotect.com ↗
The very good results obtained have allowed Alzprotect to extend the clinical trial of this treatment for 6 months, and to prepare a larger scale study. |
| 2023-02-16 | AlzProtect SAS | Results Alzprotect announces the extension of Phase 2a clinical trial for the treatment of progressive supranuclear palsy (PSP) alzprotect.com ↗
The initial C04 study (a randomised, blinded study comparing two doses of AZP2006 to placebo) showed positive and promising results. |
| 2022-09-20 | AlzProtect SAS | Results Alzprotect announces the completion of clinical trial phase 2a for the treatment of Progressive Supranuclear Palsy (PSP) alzprotect.com ↗
The primary objectives of the study were met, namely the investigational product good safety and tolerability in PSP patients. |
| 2020-08-31 | AlzProtect SAS | Regulatory Alzprotect announces the WHO approval of generic name Ezeprogind for the « first-in-Class » AZP2006 clinical stage drug alzprotect.com ↗ |
| 2019-09-18 | AlzProtect SAS | Regulatory Alzprotect obtains authorization to start a Phase 2a clinical trial in PSP alzprotect.com ↗
AlzProtect today announced that the ANSM has authorized the launch of a phase 2a clinical trial with the drug candidate AZP2006 in the indication of Progressive Supranuclear Paralysis (PSP). |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZP2006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04008355 ↗ |
| Route | Oral | “AZP2006 oral solution” NCT04008355 ↗ |